Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1980 1
1983 1
1997 1
2014 1
2017 2
2018 2
2019 3
2020 1
2021 7
2022 3
2023 3
2024 6
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: cabanas v. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.
Puig N, Agulló C, Contreras T, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Íñigo MB, Sureda A, Lakhwani S, de la Rubia J, González-Calle V, Cabañas V, Palomera L, Moraleda JM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV. Puig N, et al. Among authors: cabanas v. Blood. 2024 Dec 5;144(23):2432-2438. doi: 10.1182/blood.2024024995. Blood. 2024. PMID: 39293025
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Termini R, Žihala D, Terpos E, Perez-Montaña A, Jelínek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodriguez S, Moreno C, Perez C, Maia C, Martín-Sánchez E, Guerrero C, Botta C, Garces JJ, Lopez A, Tamariz-Amador LE, Prosper F, Bargay J, Cabezudo ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldes C, Vitoria H, Gomez C, De Arriba F, Ludwig H, Garcia-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, de la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B; PETHEMA/GEM and iMMunocell Cooperative Groups. Termini R, et al. Among authors: cabanas v. Clin Cancer Res. 2022 Nov 1;28(21):4771-4781. doi: 10.1158/1078-0432.CCR-22-1594. Clin Cancer Res. 2022. PMID: 36074126
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. Among authors: cabanas v. J Clin Oncol. 2025 Jan 10;43(2):125-132. doi: 10.1200/JCO.24.00635. Epub 2024 Oct 1. J Clin Oncol. 2025. PMID: 39353166
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, Hernández MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martínez-López J, Krsnik I, González ME, Casado LF, Martí JM, Encinas C, de Arriba F, Palomera L, Sampol A, González-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: cabanas v. Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531. Blood. 2023. PMID: 37506339 Free article. Clinical Trial.
Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.
Zhang DY, An DW, Yu YL, Melgarejo JD, Boggia J, Martens DS, Hansen TW, Asayama K, Ohkubo T, Stolarz-Skrzypek K, Malyutina S, Casiglia E, Lind L, Maestre GE, Wang JG, Imai Y, Kawecka-Jaszcz K, Sandoya E, Rajzer M, Nawrot TS, O'Brien E, Yang WY, Filipovský J, Graciani A, Banegas JR, Li Y, Staessen JA; International Database of Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Zhang DY, et al. Eur Heart J. 2025 Aug 8;46(30):2974-2987. doi: 10.1093/eurheartj/ehaf220. Eur Heart J. 2025. PMID: 40249369 Free PMC article.
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells.
Ortiz de Landazuri I, Oliver-Caldés A, Español-Rego M, Agulló C, Contreras MT, Zabaleta A, Puig N, Cabañas V, González-Calle V, Zugasti I, Inogés S, Rodríguez Otero P, Martin-Antonio B, Reguera JL, López-Diaz de Cerio A, Aróstegui JI, Uribe-Herranz M, Benítez-Ribas D, Rodríguez-Lobato LG, González EA, Tovar N, Charry P, Navarro S, Rosiñol L, Tréboles K, Mora G, Yagüe J, Moraleda JM, Urbano-Ispizua Á, Mateos MV, Pascal M, Paiva B, Juan M, Fernández de Larrea C. Ortiz de Landazuri I, et al. Among authors: cabanas v. Br J Haematol. 2024 Oct;205(4):1346-1355. doi: 10.1111/bjh.19589. Epub 2024 Jun 18. Br J Haematol. 2024. PMID: 38894496
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Burgos L, et al. Among authors: cabanas v. J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930848
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma.
Uribe-Herranz M, Oliver-Caldés A, Martínez-Micaelo N, Español-Rego M, Val-Casals M, Martínez-Soler R, Rubio-Garcia E, Brunello V, Mihelic EZ, Klein-González N, Benítez-Ribas D, Amigó N, Vergara A, Ortiz-Maldonado V, Rodríguez-Lobato LG, Delgado J, Ortiz de Landazuri I, González-Calle V, Cabañas V, Martin-Antonio B, Pérez-Amill L, Reguera-Ortega JL, Rodríguez-Otero P, Paiva B, Martínez-López J, Mateos MV, Pascal M, Urbano-Ispizua Á, González-Navarro EA, Fernández de Larrea C, Juan M. Uribe-Herranz M, et al. Among authors: cabanas v. Blood Cancer Discov. 2025 Sep 3;6(5):484-504. doi: 10.1158/2643-3230.BCD-24-0203. Blood Cancer Discov. 2025. PMID: 40643584
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.
Zugasti I, Tormo-Ratera M, Oliver-Caldés A, Soler-Perromat JC, González-Calle V, Moreno DF, Cabañas V, López-Muñoz N, Bartolomé-Solanas Á, Español-Rego M, Reguera-Ortega JL, Rosiñol L, López-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EA, Martínez-López J, Mateos MV, Tomás X, Setoain X, Fernández de Larrea C. Zugasti I, et al. Among authors: cabanas v. Blood Adv. 2025 Feb 11;9(3):571-582. doi: 10.1182/bloodadvances.2024014360. Blood Adv. 2025. PMID: 39602341 Free PMC article. Clinical Trial.
38 results